United States Diabetes Device Market Forecast Report by Types (Self-Monitoring Devices, Continuous Glucose-Monitoring Devices, Insulin Pumps, Insulin Pens), End User (Hospitals, Diagnostics Centers, Homecare), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Diabetes Clinics/Centers, Online Pharmacies) and Company Analysis 2024-2032
Buy NowUnited States Diabetes Device Market Size
United States Diabetes Device market is expected to reach US$ 8.67 Billion in 2023 to US$ 16.25 Billion by 2032, with a CAGR of 7.23 % from 2024 to 2032. The aging population, rising diabetes rates as a result of lifestyle modifications, rising obesity rates, and expensive medical expenses are all major drivers of this region's growth. In addition, the market is being driven by the application of artificial intelligence (AI) and data analytics in diabetic devices, as well as the use of smart devices.
United States Diabetes Device Overview
Over the past 20 years, there has been a significant rise in the prevalence of diabetes in the United States. This increase can be attributed to changes in lifestyle and an increase in the prevalence of obesity. One of the chronic diseases with the fastest rate of growth in the US is diabetes. Every year, 1.75 million Americans are given a diabetes diagnosis. Additionally, the nation has the largest rate of obesity, which is a major contributor to type 2 diabetes.
Recent studies, according to the AACE (American Association of Clinical Endocrinologists), have revealed that 22.2-26.9% of patients hospitalized for severe condition reported having diabetes. In hospitalized coronavirus patients, diabetes and elevated glucose levels are linked to an increased risk of complications, respiratory failure, and fatality.
According to the most current report from January 2022, diabetes is still a major health problem in the US that affects a large number of people. People with diabetes make up about 34.2 million people, or 10.5% of the total population. Both diagnosed and undiagnosed cases are included in this number.
Around 90–95% of all instances of diabetes that are diagnosed in the US fall into the type 2 diabetes category. Obesity, physical inactivity, and unhealthy eating habits are all strongly linked to type 2 diabetes.
Type 1 diabetes still affects a large number of people, especially in children and young adults, despite being less common. About 1.6 million Americans are thought to suffer from type 1 diabetes.
| Report Features | Details |
|
Base Year |
2023 |
|
Forecast Years |
2024 - 2032 |
|
Historical Years |
2019 - 2023 |
|
Market Size in 2023 |
US$ 8.67 Billion |
|
Market Forecast in 2032 |
US$ 16.25 Billion |
|
Market Growth Rate (2024-2032) |
7.23% |
Growth Drivers for the United States Diabetes Device Market
Growing Rates of Pre-Diabetes and Diabetes among Adults in the United States
Blood glucose readings over the optimal range are indicative of pre-diabetes and rising diabetes. Elevated blood glucose levels lead to a host of health problems and harm vital organs, including the heart, neurological issues, eye problems, kidneys, and eyes in the elderly. According to NIDDKD estimates, 38.4 million Americans aged 18 and older had diabetes in 2021, accounting for 11.6% of the nation's total population. Only 29.7 million of them have received a diagnosis. In addition, there are 3,52,000 adults and children under the age of 20 and 304,000 of them have type 1 diabetes.
Furthermore, the prevalence of diagnosed diabetes was highest among adults who were native to Alaska and were born in India (13.6%), then non-Hispanic whites (6.9%), Hispanics (11.7%), and non-Hispanic blacks (12.1%).
The Need for Diabetes Management Rises with the Increasing Economic Burden of Diabetes
Diabetes is becoming more and more expensive, making individual management necessary. According to estimates, the overall cost of diabetes in the United States in 2022 will be USD 412.9 billion, comprising direct medical costs to control blood glucose of USD 306.6 billion and indirect medical costs of USD 106.3 billion. The average yearly expenditure of diabetics is approximately USD 19,736; of this amount, approximately USD 12,022 is directly related to consequences from diabetes.
Almost 17% of all expenses related to diabetes are related to diabetic supplies and glucose-lowering medications. The expenses associated with indirect effects include lost productivity from early deaths (USD 32.4 billion), medication-related presenteeism (USD 35.8 billion), and decreased employment due to disability (USD 28.3 billion).
United States Diabetes Device Company Analysis
The major participants in the United States Diabetes Device market includes BD, Roche, Medtronic, Insulet Corporation, Abbott Laboratories, Dexcom Inc., Tandem Diabetes Care, Ypsomed AG, Novo Nordisk A/S, Eli Lilly.
United States Diabetes Device Company News
In October 2023, together with Phillips Medisize, GlucoModicum announced the creation of non-invasive, needle-free CGM.
In August 2023, Roche has received approval from the US Food and Drug Administration (FDA) for their Accu-Chek Solo micropump system, an insulin-using diabetic "patch" pump that does not require tubing.
In May 2023, the acquisition of EOFlow Co., a producer of wearable and disposable insulin delivery devices, was announced by Medtronic plc.
In February 2023, Automated Glucose Control LLC (AGC), a California-based business that specialized in automated insulin delivery technology, sold its assets to Insulet Corporation.
Types- Industry is divided into 4 viewpoints:
- Self-Monitoring Devices
- Continuous Glucose-Monitoring Devices
- Insulin Pumps
- Insulin Pens
End User- Industry is divided into 4 viewpoints:
- Hospitals
- Diagnostics Centers
- Homecare
Distribution Channel - Industry is divided into 4 viewpoints:
- Hospital Pharmacies
- Retail Pharmacies
- Diabetes Clinics/Centers
- Online Pharmacies
All companies have been covered with 5 Viewpoints
- Overviews
- Key Person
- Recent Developments & Strategies
- Product Portfolio & Product Launch in Last 1 Year
- Revenue
Company Analysis
- BD
- Roche
- Medtronic
- Insulet Corporation
- Abbott Laboratories
- Dexcom Inc.
- Tandem Diabetes Care
- Ypsomed AG
- Novo Nordisk A/S
- Eli Lilly
Report Details:
| Report Features | Details |
| Base Year |
2023 |
| Historical Period |
2019 - 2023 |
| Forecast Period |
2024 - 2032 |
| Market |
US$ Billion |
| Segment Covered | Types, End User and Distribution Channel |
| Companies Covered |
|
| Customization Scope |
20% Free Customization |
| Post-Sale Analyst Support |
1 Year (52 Weeks) |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
Customization Services available
- Analysis of Market Size and Its Segments
- More Company Profiles (Upto 10 without any additional cost):
- Additional Countries (Other than mentioned Countries):
- Region/Country Specific Reports:
- Market Entry Strategy:
- Region-Specific Market Dynamics:
- Regional Market Share Analysis:
- Trade Analysis:
- Production Insights:
- Others Customized Requests:
For more information contact our analysts.
Need More Assistance?
- Talk to our analysts to get more precious information on the current market trends.
- Include more countries and segments and customize the report based on the final requirement.
- Get a competitive advantage in your industry by knowing the report findings and making a positive impact on your revenues and operations.
- Our analysts are always ready to provide more help and pertinent information if you need any additional assistance.
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. United States Diabetes Devices Market
6. United States Diabetes Population
6.1 Type 1 Diabetes
6.2 Type 2 Diabetes
7. Market Share Analysis
7.1 By Types
7.2 By End User
7.3 By Distribution Channel
8. Types
8.1 Self-Monitoring Devices
8.1.1 Test Strips
8.1.2 Lancets
8.1.3 Blood Glucose Meters
8.2 Continuous Glucose-Monitoring Devices
8.2.1 Sensors
8.2.2 Transmitter
8.2.3 Receiver
8.3 Insulin Pumps
8.3.1 Patch Pumps
8.3.2 Tethered Pumps
8.3.3 Consumables
8.4 Insulin Pens
8.4.1 Disposable Insulin Pen
8.4.2 Reusable Insulin Pen
9. End User
9.1 Hospitals
9.2 Diagnostics Centers
9.3 Homecare
10. Distribution Channel
10.1 Hospital Pharmacies
10.2 Retail Pharmacies
10.3 Diabetes Clinics/Centers
10.4 Online Pharmacies
11. Porters Five Forces
11.1 Bargaining Power of Buyer
11.2 Bargaining Power of Supplier
11.3 Threat of New Entrants
11.4 Rivalry among Existing Competitors
11.5 Threat of Substitute Products
12. SWOT Analysis
12.1 Strengths
12.2 Weaknesses
12.3 Opportunities
12.4 Threats
13. Reimbursement Policies
13.1 CGM Devices in United States
13.2 Blood Glucose Devices in United States
13.3 Insulin Pump Products in United States
13.4 Insulin Pen in United States
14. Key Players Analysis
14.1 BD
14.1.1 Overviews
14.1.2 Key Person
14.1.3 Recent Developments & Strategies
14.1.4 Product Portfolio & Product Launch in Last 1 Year
14.1.5 Revenue
14.2 Roche
14.2.1 Overviews
14.2.2 Key Person
14.2.3 Recent Developments & Strategies
14.2.4 Product Portfolio & Product Launch in Last 1 Year
14.2.5 Revenue
14.3 Medtronic
14.3.1 Overviews
14.3.2 Key Person
14.3.3 Recent Developments & Strategies
14.3.4 Product Portfolio & Product Launch in Last 1 Year
14.3.5 Revenue
14.4 Insulet Corporation
14.4.1 Overviews
14.4.2 Key Person
14.4.3 Recent Developments & Strategies
14.4.4 Product Portfolio & Product Launch in Last 1 Year
14.4.5 Revenue
14.5 Abbott Laboratories
14.5.1 Overviews
14.5.2 Key Person
14.5.3 Recent Developments & Strategies
14.5.4 Product Portfolio & Product Launch in Last 1 Year
14.5.5 Revenue
14.6 Dexcom Inc.
14.6.1 Overviews
14.6.2 Key Person
14.6.3 Recent Developments & Strategies
14.6.4 Product Portfolio & Product Launch in Last 1 Year
14.6.5 Revenue
14.7 Tandem Diabetes Care
14.7.1 Overviews
14.7.2 Key Person
14.7.3 Recent Developments & Strategies
14.7.4 Product Portfolio & Product Launch in Last 1 Year
14.7.5 Revenue
14.8 Ypsomed AG
14.8.1 Overviews
14.8.2 Key Person
14.8.3 Recent Developments & Strategies
14.8.4 Product Portfolio & Product Launch in Last 1 Year
14.8.5 Revenue
14.9 Novo Nordisk A/S
14.9.1 Overviews
14.9.2 Key Person
14.9.3 Recent Developments & Strategies
14.9.4 Product Portfolio & Product Launch in Last 1 Year
14.9.5 Revenue
14.10 Eli Lilly
14.10.1 Overviews
14.10.2 Key Person
14.10.3 Recent Developments & Strategies
14.10.4 Product Portfolio & Product Launch in Last 1 Year
14.10.5 Revenue
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com